The reporter recently learned from the Ministry of Science and Technology that the "Twelfth Five-Year Plan for Biotechnology Development" and "The Twelfth Five-Year Plan for the Special Scientific and Technological Development of the Medical Device Industry" drafted by the Ministry of Science and Technology and other relevant ministries and commissions have been drafted. Special plans for the development of medical science and technology and the "12th Five-Year Plan for advanced biological manufacturing science and technology development" have formed consultation drafts and are expected to be announced in late August and early September.
Develop 30 innovative drugs
"The 12th Five-Year Plan for Biotechnology Development" pointed out that biotechnology is a green high-tech. It has a wide range of radiation and strong permeability. It can become a support and leading technology for the realization of strategic transformation in many areas of the national economy, and it is also a development strategy emerging industry. The core technology.
It is estimated that the total funds required for the implementation of the "plan" will be 150 billion yuan. In terms of financing methods, it adheres to the principle of diversification, including 50 billion yuan of central government funds, 30 billion yuan of local fiscal funds, and 70 billion yuan of self-raised funds. Among them, the central government funds 50 billion yuan, the country's major special projects 20 billion yuan, the state 973 plan 5 billion yuan, 863 plans 5 billion yuan, science and technology support plans 5 billion yuan, and the remaining related plans 15 billion yuan.
"Planning" predicts that by the end of 2015, the output value of bio-agriculture and bio-pharmaceuticals will have reached more than 200 billion yuan, and the industrial bio-technology output value will reach more than 400 billion yuan. To cultivate more than 10 listed companies in the biological and pharmaceutical fields, the average annual growth rate of the bio-industry output value remains above 15%. Form 100 biotechnology R&D and industrialization bases and 20-30 scientific and technological innovation teams.
The "planning" also proposes to cultivate a batch of new strategic industries, including the creation of major new drugs, the prevention of infectious diseases such as AIDS, the development of vaccine antibody products, and the development of bio-energy products.
With regard to the creation of major new drugs, the "Plan" proposes that in order to meet the needs of the people for basic drug use and foster the development of the pharmaceutical industry, breakthroughs will be made in a number of key technologies and production processes for the creation of drugs, 30 innovative drugs will be developed, and about 200 large drug varieties will be transformed. The creation of new drugs and important modern technology platforms, the establishment of a number of strategic alliances for technological innovation in the pharmaceutical industry, the formation of a national drug innovation system with Chinese characteristics, and enhancement of independent research and development capabilities and industrial competitiveness of pharmaceutical companies.
In the prevention and treatment of major communicable diseases such as AIDS and viral hepatitis, the major needs for raising the health of the population and maintaining social harmony and stability focus on AIDS, viral hepatitis, tuberculosis, and other major infectious diseases, breaking through diagnostic tests, forecasting, and vaccine development. And key technologies such as clinical treatment, the development of 150 diagnostic reagents, including more than 20 kinds of registration certificates; more than 10 new vaccines into clinical trials. By 2015, the emergency and comprehensive prevention and control capabilities of major communicable diseases will be significantly improved, effectively reducing new HIV infections, viral hepatitis and tuberculosis infection rates and mortality.
Yu Mingde, vice president of the China Pharmaceutical Enterprise Management Association, said that by 2015, the original capacity of the Chinese pharmaceutical industry will be significantly improved. “In the past, everyone said that we were a big imitation country and there were few truly original ones. Through the support of a series of projects such as 863 and 973, it was estimated that through the rolling development of the major new drug project during the “Eleventh Five-Year Plan†period, it was expected to be at the end of the Twelfth Five-Year Plan period. We have about 25 original medicines with independent intellectual property rights that will be industrialized. On average, there are 4 to 5 products in each year, which is a huge change.â€
Change the situation of imitation
According to the "12th Five-Year Plan for Scientific and Technological Development of the Medical Device Industry," the development principle of the medical device industry is to strive for the pricing power and dominance of medical device products. Based on independent innovation, we strive to break through a number of major technological bottlenecks, create a batch of major products, optimize the industrial structure, change the mode of economic development, and change the situation based on imitation, so that innovation really becomes an important driving force for industrial development; on the other hand, Strengthen the demonstration application of innovative products, optimize the application environment and improve the policy environment, change the image of domestic medical device products, actively expand the domestic demand market, and boost the rapid development of the medical industry.
According to Bai Zhipeng, secretary-general of the China Medical Equipment Association, medical devices are the most important basic equipment in the construction of medical service systems and public health systems. In recent years, with the support of the national finance, the overall level of China's primary medical equipment has greatly improved, but the overall pattern of equipment allocation of basic medical institutions in China has not changed, and there are still few functions, low performance, and bad use. Applicable and other issues. The equipment in major cities, large hospitals, and especially tertiary hospitals, has reached or approached the equipment level of general hospitals in developed countries. However, large and medium-sized medical equipment, high-end medical equipment, and high-value consumable products are mainly imported, and the price is high, which brings a heavy burden on the country and patients.
"More than 90% of medical equipment produced by domestic companies is medium- and low-grade products. Shanghai Kangdelai, which manufactures needles, has very thin profits. Large-scale equipment products rely on imports," he said.
Therefore, the "Plan" proposes that by 2015, initially establish and improve the medical device R & D and innovation chain, significantly enhance China's innovative ability in medical device R & D, some areas close to the level of developed countries, research and development of a number of major products with independent intellectual property rights and high performance , high quality, low cost, intelligent, digital and suitable products. The product target is to break through 20-30 key core technologies and key components and create 80 to 100 new preventive, diagnostic, therapeutic, rehabilitation and emergency medical device products that are urgently needed clinically to meet the demand for configuration and to promote the advancement of medical technology. The industrial goal is to support 10 to 15 large-scale medical device enterprise groups, 40 to 50 innovative high-tech enterprises, and establish 8 to 10 medical device technology industry bases.
Bai Zhipeng believes that the "plan" is designed very reasonable. China's medical equipment and equipment industry needs to be integrated. There is a lack of large-scale medical equipment and equipment companies. Aircraft carriers in the field of medical equipment and equipment production should be built. The largest medical device company in China, Mindray Medical International Co., Ltd. has sales of US$700 million in 2010. This is equivalent to sales of large foreign medical device companies in China. In addition, a modern enterprise system should be implemented to cultivate a group of visionary and ambitious entrepreneurs.
More innovative practical applications of medicine
"The 12th Five-Year Plan for the Development of Medical Science and Technology" pointed out that independent innovation is used as a strategic basis for the development of medical science and technology prospective research, making full use of China's rapid development of life science research, the richness of clinical medicine resources, and the strong originality of Chinese medicine theory. , Basic layout, application, research and development of the overall layout, prevention, diagnosis, treatment, rehabilitation, health research convergence, vigorously promote cross-disciplinary integration, establish a more complete and more efficient medical science and technology innovation system, accelerate the knowledge of the medical field Discovery, technological innovation, product development, and practical enhancements improve the overall ability and level of medical and health services.
The "planning" pointed out that basing on prevention and reducing disease, it is possible to fundamentally change the unfavorable situation in China's overall disease prevention and control situation. The direction of medical science and technology development is moving forward. From the prevention and control of diseases to the promotion of health, we must vigorously develop health status identification technology, health management, and sub-health state intervention technologies, and pay attention to the popularization of public health knowledge. Moved to "prevention of disease" and health care, from "passive medical care" to "active health."
"Planning" believes that the focus of medical science and technology research must be shifted downwards. The grassroots level in rural areas and communities is the key and difficult point in China's health work, and is the weak link in the disease prevention and control system. This not only focuses on cash technology products that are suitable for large cities and large hospitals, but also needs to actively develop suitable technologies and products suitable for basic conditions suitable for China's national conditions, vigorously promote the technical level and service capabilities of primary medical institutions, and build up disease prevention. The first line of defense and health promotion.
The focus of medical science and technology development is to develop genome technology, transcriptome technology, proteomics technology, metabolomics technology, epigenetic group technology, structural genome technology, and other types of histological research technologies, to develop a new generation of sequencing technology, high-throughput samples Analytical techniques. Focusing on medical informatics, bioinformatics, and computational biology, we develop high-throughput biomedical data analysis and text mining technologies to support genome-wide association analysis, epigenetics, metagenomics, stem cells, and tissue engineering.
According to relevant sources from the Ministry of Science and Technology, the "plan" will be released in late August and early September. In the past, China’s investment in medical science and technology was relatively limited, and the development of medical science and technology was relatively weak. Nowadays, medical science is developing in the direction of multidisciplinary and large-scale integration. From the point of view of people's livelihood, China's demand for medical science and technology is urgent, and the diagnosis and treatment technology needs to be accelerated. From the organizational model, we must adapt to the requirements of modern medical development, strengthen resource integration, grasp the frontier direction, and accelerate the transformation of high-tech to medical applications.
He pointed out that compared with developed countries, China has a large scientific research team and rich case resources, but the lack of original medical results, lack of standardized research results, and insufficient research quality. The core issue of the “Planning†is the creation of the overall environment and changes in the model. The ultimate goal of independent innovation is to create a better atmosphere for innovation, improve the efficiency of innovation and solve practical problems, and promote more practical innovations. It is not entirely a high-tech innovation that integrates strength and resources.
“China currently has the problem of difficulty in seeing a doctor and expensive medical treatment. The main reason is that high levels of medical resources are scarce.†He said that one of the priorities of the “planning†is to implement an integrated medical service model to solve the problem of difficult medical care and expensive medical services. . The integrated medical service model mainly includes data integration, knowledge integration, and service integration. It has built large-scale top-three hospitals, municipal-level central hospitals, and county and township primary medical institutions into networks, and achieved rapid medical advancement and diffusion of medical diffusion through digital medical technologies. Medical standards have improved.
Develop 30 innovative drugs
"The 12th Five-Year Plan for Biotechnology Development" pointed out that biotechnology is a green high-tech. It has a wide range of radiation and strong permeability. It can become a support and leading technology for the realization of strategic transformation in many areas of the national economy, and it is also a development strategy emerging industry. The core technology.
It is estimated that the total funds required for the implementation of the "plan" will be 150 billion yuan. In terms of financing methods, it adheres to the principle of diversification, including 50 billion yuan of central government funds, 30 billion yuan of local fiscal funds, and 70 billion yuan of self-raised funds. Among them, the central government funds 50 billion yuan, the country's major special projects 20 billion yuan, the state 973 plan 5 billion yuan, 863 plans 5 billion yuan, science and technology support plans 5 billion yuan, and the remaining related plans 15 billion yuan.
"Planning" predicts that by the end of 2015, the output value of bio-agriculture and bio-pharmaceuticals will have reached more than 200 billion yuan, and the industrial bio-technology output value will reach more than 400 billion yuan. To cultivate more than 10 listed companies in the biological and pharmaceutical fields, the average annual growth rate of the bio-industry output value remains above 15%. Form 100 biotechnology R&D and industrialization bases and 20-30 scientific and technological innovation teams.
The "planning" also proposes to cultivate a batch of new strategic industries, including the creation of major new drugs, the prevention of infectious diseases such as AIDS, the development of vaccine antibody products, and the development of bio-energy products.
With regard to the creation of major new drugs, the "Plan" proposes that in order to meet the needs of the people for basic drug use and foster the development of the pharmaceutical industry, breakthroughs will be made in a number of key technologies and production processes for the creation of drugs, 30 innovative drugs will be developed, and about 200 large drug varieties will be transformed. The creation of new drugs and important modern technology platforms, the establishment of a number of strategic alliances for technological innovation in the pharmaceutical industry, the formation of a national drug innovation system with Chinese characteristics, and enhancement of independent research and development capabilities and industrial competitiveness of pharmaceutical companies.
In the prevention and treatment of major communicable diseases such as AIDS and viral hepatitis, the major needs for raising the health of the population and maintaining social harmony and stability focus on AIDS, viral hepatitis, tuberculosis, and other major infectious diseases, breaking through diagnostic tests, forecasting, and vaccine development. And key technologies such as clinical treatment, the development of 150 diagnostic reagents, including more than 20 kinds of registration certificates; more than 10 new vaccines into clinical trials. By 2015, the emergency and comprehensive prevention and control capabilities of major communicable diseases will be significantly improved, effectively reducing new HIV infections, viral hepatitis and tuberculosis infection rates and mortality.
Yu Mingde, vice president of the China Pharmaceutical Enterprise Management Association, said that by 2015, the original capacity of the Chinese pharmaceutical industry will be significantly improved. “In the past, everyone said that we were a big imitation country and there were few truly original ones. Through the support of a series of projects such as 863 and 973, it was estimated that through the rolling development of the major new drug project during the “Eleventh Five-Year Plan†period, it was expected to be at the end of the Twelfth Five-Year Plan period. We have about 25 original medicines with independent intellectual property rights that will be industrialized. On average, there are 4 to 5 products in each year, which is a huge change.â€
Change the situation of imitation
According to the "12th Five-Year Plan for Scientific and Technological Development of the Medical Device Industry," the development principle of the medical device industry is to strive for the pricing power and dominance of medical device products. Based on independent innovation, we strive to break through a number of major technological bottlenecks, create a batch of major products, optimize the industrial structure, change the mode of economic development, and change the situation based on imitation, so that innovation really becomes an important driving force for industrial development; on the other hand, Strengthen the demonstration application of innovative products, optimize the application environment and improve the policy environment, change the image of domestic medical device products, actively expand the domestic demand market, and boost the rapid development of the medical industry.
According to Bai Zhipeng, secretary-general of the China Medical Equipment Association, medical devices are the most important basic equipment in the construction of medical service systems and public health systems. In recent years, with the support of the national finance, the overall level of China's primary medical equipment has greatly improved, but the overall pattern of equipment allocation of basic medical institutions in China has not changed, and there are still few functions, low performance, and bad use. Applicable and other issues. The equipment in major cities, large hospitals, and especially tertiary hospitals, has reached or approached the equipment level of general hospitals in developed countries. However, large and medium-sized medical equipment, high-end medical equipment, and high-value consumable products are mainly imported, and the price is high, which brings a heavy burden on the country and patients.
"More than 90% of medical equipment produced by domestic companies is medium- and low-grade products. Shanghai Kangdelai, which manufactures needles, has very thin profits. Large-scale equipment products rely on imports," he said.
Therefore, the "Plan" proposes that by 2015, initially establish and improve the medical device R & D and innovation chain, significantly enhance China's innovative ability in medical device R & D, some areas close to the level of developed countries, research and development of a number of major products with independent intellectual property rights and high performance , high quality, low cost, intelligent, digital and suitable products. The product target is to break through 20-30 key core technologies and key components and create 80 to 100 new preventive, diagnostic, therapeutic, rehabilitation and emergency medical device products that are urgently needed clinically to meet the demand for configuration and to promote the advancement of medical technology. The industrial goal is to support 10 to 15 large-scale medical device enterprise groups, 40 to 50 innovative high-tech enterprises, and establish 8 to 10 medical device technology industry bases.
Bai Zhipeng believes that the "plan" is designed very reasonable. China's medical equipment and equipment industry needs to be integrated. There is a lack of large-scale medical equipment and equipment companies. Aircraft carriers in the field of medical equipment and equipment production should be built. The largest medical device company in China, Mindray Medical International Co., Ltd. has sales of US$700 million in 2010. This is equivalent to sales of large foreign medical device companies in China. In addition, a modern enterprise system should be implemented to cultivate a group of visionary and ambitious entrepreneurs.
More innovative practical applications of medicine
"The 12th Five-Year Plan for the Development of Medical Science and Technology" pointed out that independent innovation is used as a strategic basis for the development of medical science and technology prospective research, making full use of China's rapid development of life science research, the richness of clinical medicine resources, and the strong originality of Chinese medicine theory. , Basic layout, application, research and development of the overall layout, prevention, diagnosis, treatment, rehabilitation, health research convergence, vigorously promote cross-disciplinary integration, establish a more complete and more efficient medical science and technology innovation system, accelerate the knowledge of the medical field Discovery, technological innovation, product development, and practical enhancements improve the overall ability and level of medical and health services.
The "planning" pointed out that basing on prevention and reducing disease, it is possible to fundamentally change the unfavorable situation in China's overall disease prevention and control situation. The direction of medical science and technology development is moving forward. From the prevention and control of diseases to the promotion of health, we must vigorously develop health status identification technology, health management, and sub-health state intervention technologies, and pay attention to the popularization of public health knowledge. Moved to "prevention of disease" and health care, from "passive medical care" to "active health."
"Planning" believes that the focus of medical science and technology research must be shifted downwards. The grassroots level in rural areas and communities is the key and difficult point in China's health work, and is the weak link in the disease prevention and control system. This not only focuses on cash technology products that are suitable for large cities and large hospitals, but also needs to actively develop suitable technologies and products suitable for basic conditions suitable for China's national conditions, vigorously promote the technical level and service capabilities of primary medical institutions, and build up disease prevention. The first line of defense and health promotion.
The focus of medical science and technology development is to develop genome technology, transcriptome technology, proteomics technology, metabolomics technology, epigenetic group technology, structural genome technology, and other types of histological research technologies, to develop a new generation of sequencing technology, high-throughput samples Analytical techniques. Focusing on medical informatics, bioinformatics, and computational biology, we develop high-throughput biomedical data analysis and text mining technologies to support genome-wide association analysis, epigenetics, metagenomics, stem cells, and tissue engineering.
According to relevant sources from the Ministry of Science and Technology, the "plan" will be released in late August and early September. In the past, China’s investment in medical science and technology was relatively limited, and the development of medical science and technology was relatively weak. Nowadays, medical science is developing in the direction of multidisciplinary and large-scale integration. From the point of view of people's livelihood, China's demand for medical science and technology is urgent, and the diagnosis and treatment technology needs to be accelerated. From the organizational model, we must adapt to the requirements of modern medical development, strengthen resource integration, grasp the frontier direction, and accelerate the transformation of high-tech to medical applications.
He pointed out that compared with developed countries, China has a large scientific research team and rich case resources, but the lack of original medical results, lack of standardized research results, and insufficient research quality. The core issue of the “Planning†is the creation of the overall environment and changes in the model. The ultimate goal of independent innovation is to create a better atmosphere for innovation, improve the efficiency of innovation and solve practical problems, and promote more practical innovations. It is not entirely a high-tech innovation that integrates strength and resources.
“China currently has the problem of difficulty in seeing a doctor and expensive medical treatment. The main reason is that high levels of medical resources are scarce.†He said that one of the priorities of the “planning†is to implement an integrated medical service model to solve the problem of difficult medical care and expensive medical services. . The integrated medical service model mainly includes data integration, knowledge integration, and service integration. It has built large-scale top-three hospitals, municipal-level central hospitals, and county and township primary medical institutions into networks, and achieved rapid medical advancement and diffusion of medical diffusion through digital medical technologies. Medical standards have improved.
UVB is present in natural sunlight and is an effective treatment for psoriasis. UVB penetrates the skin and slows the growth of affected skin cells. Treatment using UVB can include UVB phototherapy, excimer laser, or in-office or home UVB phototherapy.
Treating psoriasis with home UVB phototherapy can be an economical and convenient choice. Like phototherapy in a health care provider`s office or clinic, it requires a consistent treatment schedule. 
UVB Phototherapy,Uvb Light Therapys,Uv Light Therapy,Narrow Band Uvb ,Uvb Lamp Psoriasis
Ningbo Queen Electronic Science Technology Co., Ltd , https://www.queenmeds.com